An interventional study of Prehabilitation (Structured Preoperative Exercise Programme) in Non-Small Cell Lung Cancer, sponsored by Hacettepe University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.
Sponsored by Hacettepe University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 255 studies in Carcinoma, Non-Small-Cell Lung with a site in Turkey — 62 open to participants now, 145 under way, 94 of them phase 3. Carcinoma, Non-Small-Cell Lung · Turkey.
Among the 255 studies in Carcinoma, Non-Small-Cell Lung with a site in Turkey, this one is the 217th largest by planned enrollment of the 242 interventional ones that give a count, is one of 14 that started in 2026, is one of 10 with no phase, reaches primary completion later than 60 of the 144 other live ones, and was the 247th registered.
7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →62 of the 255 studies in Carcinoma, Non-Small-Cell Lung with a site in Turkey are open now. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Turkey, United States, Argentina and 10 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Turkey, United States, Argentina and 13 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Turkey, United States, Argentina and 15 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Turkey, United States, Australia and 17 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Turkey, Argentina, Australia and 16 more countries
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
255 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 62 · Phase 3 166 · Phase 4 4
First in 2001; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 62 is close to the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 413 across the 242 interventional studies, 153 across the 12 observational. Of the 107 that completed or were terminated, 77 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
233 of 255 have an industry lead sponsor. The 10 most frequent:
Hacettepe University is the lead sponsor of 1,009 studies on the registry; 214 are open to participants now.
Hacettepe University has 5 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
33 of the studies in Carcinoma, Non-Small-Cell Lung with a site in Turkey that are under way reach primary completion within a year, 19 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT06430866Phase 3AmgenPharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) | 2026-12-14 |
| NCT07162883Phase 3Qilu Pharmaceutical Co., Ltd.Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | 2026-12-31 |
| NCT05221840Phase 3AstraZenecaA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | 2027-01-08 |
| NCT05609968Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) | 2027-01-12 |
Add all 33 to your calendar (.ics) → With an account.
Among the 255 studies in Carcinoma, Non-Small-Cell Lung with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
INTRODUCTION: Lung cancer is among the leading cancers, and surgery has a major role in treatment. Patients diagnosed with Non-Small Cell Lung Cancer (NSCLC) who are eligible for surgical treatment have a high risk of experiencing postoperative complications. Therefore, in recent years, the concept of prehabilitation has begun to gain importance. Within the scope of prehabilitation practices, patients are provided with programmes that include aerobic exercises and breathing exercises in the preoperative period.
AIM: This study aims to evaluate the effects of a structured exercise programme, including aerobic exercises and breathing exercises in the preoperative period, on postoperative pain severity, surgical recovery level, length of hospital stays (LOS), and quality of life (QoL) in patients diagnosed with NSCLC and planned for surgical treatment.
METHODS: The research is an experimental, parallel group-randomised controlled trial to be conducted with 62 participants followed in the Thoracic Surgery Outpatient Clinic of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital and scheduled for surgery due to NSCLC. Patients will be equally assigned to the intervention and control groups using the block randomization method. In the intervention group, in the preoperative period, for two weeks and five days per week, at least 30 minutes of walking per day will be performed; in addition, for two weeks before surgery, throughout the entire week, during waking hours, 10 repetitions with incentive spirometer every hour, and daily four sessions of deep breathing \& coughing exercises will be performed as breathing exercises. In the control group, routine preoperative clinical procedures will be applied. In the postoperative period, pain severity, surgical recovery level, LOS, and QoL will be compared between the two groups. Data will be collected face-to-face by the researcher using the "Descriptive Characteristics Form", "EQ-5D-5L Quality of Life Scale", "Numeric Rating Scale (NRS)", and "Surgical Recovery Scale". Data on the length of hospital stay will be obtained from patient files. The data will be analysed using parametric and/or nonparametric tests through the SPSS.
CONCLUSION: The findings of the study are expected to contribute to strengthening holistic care approaches for the preoperative period in surgical nursing practices and to improving patient outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prehabilitation (Structured Preoperative Exercise Programme)
Other: Prehabilitation (Structured Preoperative Exercise Programme)
Control: Partients in this arm will receive standard preoperative care without a structured exercise programme. Study-related data will be collected from patients admitted to the hospital at the end of the two-week preoperative period in accordance with the study protocol. In this regard, the measurements to be taken in the study will include: (1) Pain severity: At 6, 12, 24 and 48 hours after surgery; (2) Surgical recovery level: On the third and seventh days after surgery; (3) Quality of life: On the first day before surgery and on the seventh day after surgery. (4) In addition, patients' LOSs will be recorded.
Participants in this arm will receive a structured preoperative exercise programme starting two weeks before surgery. The programme includes moderate-intensity walking for at least 30 minutes 5 days per week, deep breathing and coughing exercises four times daily, and hourly incentive spirometry exercises while awake. Participants will record daily adherence to the exercise programme, and compliance will be monitored through daily telephone follow-up by the researcher. Study-related data will be collected from patients admitted to the hospital at the end of the two-week preoperative period in accordance with the study protocol. In this regard, the measurements to be taken in the study will include: (1) Pain severity: At 6, 12, 24 and 48 hours after surgery; (2) Surgical recovery level: On the third and seventh days after surgery; (3) Quality of life: On the first day before surgery and on the seventh day after surgery. (4) In addition, patients' LOSs will be recorded.
Health-Related Quality of Life (EQ-5D-5L)
The EQ-5D-5L is a self-reported questionnaire assessing five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five levels: no problems, mild problems, moderate problems, severe problems, and extreme problems. The questionnaire also includes a Visual Analog Scale (VAS) ranging from 0 (worst health) to 100 (best health) for participants to rate their current health status. Higher scores indicate better health.
Time frame: Change from baseline scores on the 7th postoperative day.
Postoperative Pain Intensity (Numeric Rating Scale, NRS)
The NRS is an 11-point scale (0-10) used to assess pain intensity, where 0 indicates no pain and 10 indicates the worst possible pain. Patients rate their pain at each time point, and the average of the measurements will be used to assess postoperative pain. The NRS is validated for adults, including elderly patients and those with mild-to-moderate cognitive impairment.
Time frame: Change from baseline scores on the 48 hours postoperatively.
Postoperative Surgical Recovery (Surgical Recovery Scale)
The Surgical Recovery Scale is a 13-item questionnaire assessing two sub-dimensions: "Impact on energy" and "Impact on daily activities." Items are scored using 6-point Likert scales, with higher scores indicating better recovery. The total score ranges from 8 to 73. This scale is validated with a Cronbach's α of 0.93.
Time frame: Change from baseline scores on the 7th postoperative day.
Length of Hospital Stay
Patients' discharge time will be recorded and compared in both groups.
Time frame: Approximately the seventh day.
Plan to share: No
Start is estimated for Feb 2026; primary completion for Feb 2027, 12 months later.
Of 345 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 97. This study's planned 12 months is below that.
Counting every sponsor, half of 361 studies reached it within 51 months; a quarter within 26 and three quarters within 97.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →